Product Classification as Ayurvedic medicaments confirmed; loan licence job work relieves principal of pre August excise liability.

Classification of the impugned formulations was determined by reference to statutory descriptions, licensing and certification as Ayurvedic medicines and application of the twin test (ingredient and common parlance); accordingly the products qualify as medicaments under Chapter 30, not cosmetics, and classification challenge succeeds for the assessee. Liability for central excise prior to August 2011 was resolved by applying the definition of manufacturer and analysing the loan licence/job work relationship; the job worker was the manufacturer for excise purposes and the appellant is not liable for that period. The appellant met the SSI exemption threshold for September 2011-February 2012, so differential duty and penalties are unsustainable absent proved suppression or mens rea.

---

---

Issues: (i) Whether the impugned products are classifiable as medicaments under Chapter 30 of the Central Excise Tariff Act, 1985 or as cosmetics under Chapter 33 of the Central Excise Tariff Act, 1985; (ii) Whether the appellant-company is liable to pay central excise duty for the period prior to August 2011 on goods manufactured by the job worker under a loan licence; (iii) Whether the appellant is entitled to SSI exemption for the period September 2011 to February 2012 in terms of Notification No. 08/2003-C.E. dated 01.03.2003 and related consequences including penalties and differential demand.

Issue (i): Whether the impugned products are medicaments under Chapter 30 or cosmetics under Chapter 33 of the Central Excise Tariff Act, 1985.

Analysis: The products were manufactured under valid Ayurvedic drug licences and certified by the Directorate of ISM Drugs Control as Ayurvedic medicines; their formulations and dosages correspond to authoritative Ayurvedic texts; labeling complied with requirements for Ayurvedic medicines; judicial precedents and the twin test (ingredient test and common parlance test) were considered. The Revenue produced no contrary expert opinion or material that effectively rebutted the licensing and certification evidence. Classification is an interpretational issue and was assessed on the statutory description and the admitted licences and certification.

Conclusion: The products are classifiable as Ayurvedic medicines/medicaments under Chapter 30 of the Central Excise Tariff Act, 1985. The conclusion is in favour of the assessee.

Issue (ii): Whether the appellant-company is liable to pay central excise duty for the period prior to August 2011 on goods manufactured by the job worker under a loan licence.

Analysis: Central excise liability rests on the manufacturer as defined under the Central Excise Act. The facts show M/s. B.D. Enterprises carried out manufacture on a principal-to-principal basis as the job worker; the loan licence arrangements and relevant precedents were examined to determine that the appellant was not the manufacturer for excise purposes for the period prior to August 2011. The adjudicating authority's finding that the job worker was exempt due to rural location does not convert the loan licensee into liable manufacturer.

Conclusion: The appellant-company is not liable to pay central excise duty for the period prior to August 2011. The conclusion is in favour of the assessee.

Issue (iii): Whether the appellant is entitled to SSI exemption for September 2011 to February 2012 and related reliefs including rejection of differential demand and penalties.

Analysis: The appellant's turnover for September 2011 to February 2012 was within the SSI exemption threshold specified in Notification No. 08/2003-C.E. dated 01.03.2003; from March 2012 the appellant obtained registration and paid duty classifying goods under Chapter 30. The extended period and imposition of penalties require suppression or mens rea which was not established. Classification disputes are interpretational and the record shows disclosure to authorities.

Conclusion: The appellant is entitled to SSI exemption for September 2011 to February 2012; no differential demand is sustainable from March 2012 onwards; and no penalty is imposable on the appellant or its director. The conclusions are in favour of the assessee.

Final Conclusion: The appeals are allowed, the impugned orders are set aside, and consequential reliefs follow; the overall effect is that the demands and penalties challenged are quashed as set out above.

Ratio Decidendi: Where products are manufactured under valid statutory drug licences, their composition and labeling conform to authoritative medicinal texts and are certified by the competent drug licensing authority, they qualify as medicaments under Chapter 30 of the Central Excise Tariff Act, 1985 and classification by the Revenue must be rebutted by cogent contrary evidence before differential duty or penalties can be sustained.

---